Last: | |||
Change: | Change(%): | ||
Volume: | Open: | ||
High: | Low: | ||
52Wk High: | 52Wk Low: |
BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. The company is in a Phase 2 trial in ALS after having seen excellent safety and efficacy in earlier clinical studies.